7 results
The aim of the present study is to causally detect whether disrupting processing in the numerosity map with TMS alters numerosity perception and/or object size perception.
To investigate the causal involvement of the ralPFC in the offset of fear (study 1) and SSRT (study 2) by temporally inhibiting this area using transcranial magnetic stimulation (TMS).
To prove that the RECAP test has the potential of selecting patients who are sensitive to treatment with the PARP inhibitor talazoparib as measured by the PFS rate at 4 months.
Primary objectiveTo demonstrate that talazoparib in combination with enzalutamide is superior to placebo in combination with enzalutamide in prolonging investigator--assessed Radiographic Progression-free Survival (rPFS), in participants with mCSPC…
PrimaryTo evaluate the efficacy of single agent talazoparib in DNA damage repair (DDR) + metastatic CRPC, as measured by best objective responserate (ORR).Secondary:To evaluate efficacy with respect to the following parameters:• Time to objective…
Primary Objective:* To evaluate ORR of avelumab in combination with talazoparib, in patients with locally advanced or metastatic solid tumors harboring BRCA1, BRCA2 or ATM defect.Secondary Objective:* To assess the overall safety and tolerability of…
Primary ObjectiveThe primary objective of this study is to determine whether nSTRIDE APS is superior to HA in mean Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) LK 3.1 pain score (change from baseline to 12 months post-…